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Background. Central nervous system (CNS) dysfunction is a prominent feature of the functional gastrointestinal (GI)
disorder, irritable bowel syndrome (IBS). However, the neurobiological and cognitive consequences of key pathophysio-
logical features of IBS, such as stress-induced changes in hypothalamic–pituitary–adrenal (HPA)-axis functioning, is
unknown. Our aim was to determine whether IBS is associated with cognitive impairment, independently of psychiatric
co-morbidity, and whether cognitive performance is related to HPA-axis function.
Method. A cross-sectional sample of 39 patients with IBS, a disease control group of 18 patients with Crohn’s disease
(CD) in clinical remission and 40 healthy age- and IQ-matched control participants were assessed using the Paired
Associates Learning (PAL), Intra-Extra Dimensional Set Shift (IED) and Spatial Working Memory (SWM) tests from
the Cambridge Neuropsychological Test Automated Battery (CANTAB) and a computerized Stroop test. HPA-axis func-
tion was determined by measuring the cortisol awakening response (CAR).
Results. IBS patients exhibited a subtle visuospatial memory deﬁcit at the PAL six- pattern stage (p=0.03),
which remained after psychiatric co-morbidity was controlled for (p=0.04). Morning cortisol levels were lower in IBS
(p=0.04) and signiﬁcantly associated with visuospatial memory performance within IBS only (p=0.02).
Conclusions. For the ﬁrst time, altered cognitive function on a hippocampal-mediated test of visuospatial memory,
which was related to cortisol levels and independent of psychiatric co-morbidity, has been identiﬁed in IBS.
Visuospatial memory impairment may be a common, but currently neglected, component of IBS. Further elucidation
of the nature of this impairment may lead to a greater understanding of the underlying pathophysiology of IBS, and
may provide novel therapeutic approaches.
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Introduction
Irritable bowel syndrome (IBS) is the most common
functional gastrointestinal (GI) disorder in Western
countries, affecting an estimated 10% of the general
population (Clarke et al. 2009b) and accounting for
up to 50% of all visits to general practitioners for
GI complaints (Wilson et al. 2004). Symptoms, which
include abdominal pain or discomfort and altered
bowel habits (Longstreth et al. 2006), are chronic
(Ford et al. 2008) in some cases debilitating, and are
cited as a leading cause of work absenteeism and pre-
senteeism (Spiegel, 2009). IBS is thus associated with a
substantial impairment in the individual sufferer’s
quality of life (Longstreth et al. 2003).
Although the pathophysiology of IBS is not fully
understood, it is best regarded as a disorder caused
by dysregulation of the complex interactions along
the brain–gut axis (Cryan & O’Mahony, 2011;
Grenham et al. 2011; Mayer & Tillisch, 2011; Collins
et al. 2012), a model describing the bidirectional com-
munication between the central, autonomic and enteric
nervous systems, involving neural, endocrine and
immune pathways (Ohman & Simren, 2007). For
example, it is thought that stress-induced changes in
hypothalamic–pituitary–adrenal (HPA)-axis function-
ing can dysregulate normal brain–gut interactions
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(Mayer, 2000) and studies from our laboratory and
others have documented abnormal HPA-axis activity
in IBS (Bohmelt et al. 2005; Dinan et al. 2006; Chang
et al. 2009). A role for low-grade immune activity in
IBS has garnered much support from experimental
studies demonstrating alterations on several immune
parameters (Barbara et al. 2004; Collins, 2005; Guilarte
et al. 2007; Ohman & Simren, 2010), including elevated
peripheral levels of pro-inﬂammatory cytokines
(Dinan et al. 2006, 2008; Liebregts et al. 2007; Scully
et al. 2010; McKernan et al. 2011) and an immune-
mediated degradation of tryptophan metabolism
along the kynurenine pathway (Fitzgerald et al.
2008; Clarke et al. 2009a, 2012). Moreover, central dys-
function is a prominent feature of IBS. Centrally acting
therapies, both psychotherapeutic (Whorwell et al.
1984, 1987; Lackner et al. 2006) and pharmacological
(Creed et al. 2003), have demonstrated efﬁcacy in the
treatment of GI symptoms in IBS. Studies commonly
report an increased prevalence of depression and
anxiety, and affected patients often have a formal, psy-
chiatrically diagnosed mood disorder (Hazlett-Stevens
et al. 2003; Creed et al. 2005, 2008; Lembo et al. 2009;
Mykletun et al. 2010). In addition, mounting evidence
from functional magnetic resonance imaging (fMRI)
research indicates that, in response to visceral pain
stimulation, patients with IBS exhibit abnormal brain
activity in regions involved in pain processing and
endogenous pain modulation (Mayer et al. 2009;
Tillisch et al. 2011). However, a largely understudied
and potentially underestimated manifestation of
brain–gut axis dysfunction in IBS is cognitive impair-
ment (Kennedy et al. 2012).
To date, the few studies assessing cognitive perform-
ance in IBS are in line with a cognitive behavioural
framework (Sharpe et al. 1992; Creed, 2007; Spence &
Moss-Morris, 2007) by demonstrating that patients
exhibit attentional biases to GI symptom-related
stimuli (Gibbs-Gallagher et al. 2001; Afzal et al. 2006;
Posserud et al. 2009; Martin & Chapman, 2010;
Chapman & Martin, 2011) or negatively valenced
words (Gomborone et al. 1993). However, we recently
proposed a cognitive neurobiological model whereby
some of the key pathophysiological features of IBS,
including stress, immune activation and chronic pain,
may impact not only on emotion- or symptom-related
cognition but also on key domains of executive function,
working memory, attention and episodic memory
(Kennedy et al. 2012). This model has received support
from an fMRI study reporting impaired cognitive ﬂexi-
bility on the Wisconsin Card Sorting Test (WCST),
with associated differences in regional activity in frontal
and temporal brain regions in IBS (Aizawa et al. 2012).
Although this is an important and substantial step in
elucidating the cognitive domains that are affected in
IBS, it is limited in its scope of assessment by focusing
on executive function alone. As such, the impact on
other key brain functions such as episodic and working
memory or non-emotional/symptom-related attention
in IBS remains unknown. Furthermore, there remains a
lack of understanding of how key pathophysiological
features of IBS, such as stress-induced changes in
HPA-axis functioning (Dinan et al. 2006), can impact
on the brain and lead to cognitive impairment.
Considering the prevalence of IBS and the high inci-
dence among young adult femaleswhomaybe engaged
in formal education or embarking on careers, it is of
great importance to explore the extent of cognitive
impairment in this debilitating functional GI disorder.
The current study aimed to expand on previous
ﬁndings by assessing how IBS patients perform on a
battery of cognitive tests covering cognitive ﬂexibility
and attentional set-shifting (Intra-Extra Dimensional
Set Shift; IED), working memory (Spatial Working
Memory; SMW) and visuospatial episodic memory
(Paired Associates Learning; PAL) from the Cam-
bridge Neuropsychological Test Automated Battery
(CANTAB®), and response conﬂict using the Stroop
test. Considering that IBS is a stress-related disorder,
our primary hypothesis was that, in addition to im-
paired cognitive ﬂexibility as described previously
(Aizawa et al. 2012), patients with IBS would exhibit
mild but identiﬁable hippocampal-mediated, visuo-
spatial memory dysfunction, which would be related
to HPA-axis functioning as measured by the cortisol
awakening response (CAR). In addition, we included
the SWM and Stroop tests based on the hypothesis
that impairedworkingmemoryand inhibitory respond-
ing have been identiﬁed in other conditions associated
with stress and chronic pain, such as fybromyalgia and
chronic fatigue syndrome (Glass, 2006; Moriarty et al.
2011), and thus performance on these tests may also be
compromised in IBS. We compared cognitive perform-
ance in IBS with that of a group of individuals with a
well-deﬁned inﬂammatoryGI disorder, Crohn’s disease
(CD). These patients were included as our disease con-
trol group to control for the effects of chronic GI symp-
toms. Additionally, we explicitly controlled for any
possible impact of anxiety and depression on cognitive
performance by carrying out a reanalysis of the data
where cognitive differences were identiﬁed, following
the removal of participants exhibiting clinically relevant
levels of psychiatric co-morbidity.
Method
Participants
Patients with IBS who satisﬁed Rome III criteria
(Longstreth et al. 2006) and had undergone previous
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investigation to exclude the presence of organic GI
disease, including inﬂammatory bowel disease (IBD)
and coeliac disease, and patients with CD in clinical
remission [Harvey Bradshaw Index (HBI) score <5]
were recruited from speciality clinics at Cork Uni-
versity Hospital. Healthy control participants were
recruited from the staff and student population of
University College Cork by advertisement. Patients
presenting with signiﬁcant acute or chronic coexisting
illness other than that under study were excluded.
Study participants were males and females between
18 and 50 years of age. Exclusion criteria included
use of psychoactive medications (anxiolytics, anti-
psychotics, antidepressants at a dose used to treat
depressive disorders, and opioid-based pain relievers),
regular use of non-steroidal anti-inﬂammatory drugs
(NSAIDs), antibiotic use within the prior 4 weeks,
history of alcohol abuse, evidence of immuno-
deﬁciency and recent (within 6 months) abdominal
surgery. Patients with CD were required to have at
least a 1-month wash-out period from prednisone
use prior to testing. Budesonide, which has minimal
systemic bioavailability, was allowed. Healthy con-
trol participants were excluded if they had a history
of chronic complaints, GI (not attributable to gastro-
enteritis or other clearly identiﬁable cause) or other-
wise.
Study procedures
The study protocol (APC024 2010) and all procedures
were approved by the University College Cork
Clinical Research Ethics Committee of the Cork
Teaching Hospitals and conducted in accordance
with the International Conference on Harmonization
(ICH) Good Clinical Practice (GCP) Guidelines and
the Declaration of Helsinki. Study participants meet-
ing inclusion criteria for entry provided written
informed consent before participation. A total of 97
individuals enrolled in the study. Groups were
matched on the basis of age, verbal IQ, body mass
index (BMI) and units of alcohol consumed per
week. Study visits were conducted between 0730
and 1030 h to control for endogenous ﬂuctuations
in glucocorticoid levels. On arrival at the laboratory,
a brief medical examination was carried out by an
experienced clinical research nurse who measured
participants’ vital signs, recorded their BMI and
collected a venous blood sample for assessment of
full blood count, renal function, serum electrolytes
and liver enzymes. Clinically signiﬁcant abnormal-
ities in these blood tests led to exclusion from the
study following review by an experienced physi-
cian.
Measures
Mood and GI symptom questionnaires
Symptoms of anxiety and depression were assessed
using the self-reported Hospital Anxiety and De-
pression Scale (HADS; Zigmond & Snaith, 1983) and
the nine-item Patient Health Questionnaire (PHQ-9;
Kroenke et al. 2001). Patients with IBS rated their cur-
rent abdominal pain severity on a scale from 0 (no
pain) to 100 (severe pain). CD patients completed the
HBI as a general index of current symptomatology.
Salivary cortisol analysis
HPA-axis functioning was examined by measuring the
CAR. This is a well-validated method for characteriz-
ing HPA-axis function and has been used for this pur-
pose in numerous functional and psychiatric disorders
(Fries et al. 2009). On the morning prior to their study
visit, participants were instructed to collect saliva
samples upon wakening, and at 1 h and 3 h post-
wakening. As it has not yet been established whether
variable waking times affect the CAR (for reviews,
see Fries et al. 2009; Law et al. 2013), we took the
approach that is common in the literature (Hinkelmann
et al. 2013) and did not require that participants
wake at a speciﬁc time, but followed their normal
routine as closely as possible. Waking times were
recorded for analysis to determine any group differ-
ences. Salivary samples were stored at –80 °C until
analysis. Cortisol concentrations were determined
using the Cortisol Enzyme Immunoassay Kit accord-
ing to the manufacturer’s instruction (Enzo® Life Sci-
ences, UK). The assay detection limit was 0.16 nmol/l.
Inter- and intra-assay coefﬁcients of variation (CVs)
were 11.24% and 8.2% respectively.
Cognitive assessment
Tests from the CANTAB® battery (Cambridge Cog-
nition, Ltd, UK; Robbins & Sahakian, 1994) and a
computerized Stroop word–colour interference test
(Stroop; Xavier Educational Software Ltd, UK) were
administered by a trained test administrator who
issued standardized verbal instructions to participants
on the use of a portable touch screen Sahara i440D
Slate Tablet PC (TabletKiosk, Sand Dune Ventures,
USA) running CANTABeclipse™ software. The cogni-
tive assessment lasted approximately 45min with each
participant ﬁrst completing the Big/Little Circle as a
short familiarization task, followed by the IED, PAL
and SWM tests from the CANTAB, and ﬁnally the
Stroop test. A measure of pre-morbid IQ was obtained
using the National Adult Reading Test-2 (NART-2;
Nelson & Willison, 1991) and converted to Wechsler
Adult Intelligence Scale –Revised (WAIS-R) full-scale
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IQ scores. A brief description of each cognitive test is
provided in the following sections. More detailed
information on CANTAB tests is available elsewhere
(Sahakian & Owen, 1992; Fray & Robbins, 1996).
PAL, parallel mode
PAL is a test of visuospatial episodic memory and
assesses new learning, list memory and list learning,
and has demonstrated sensitivity to changes in the
function of hippocampal brain regions (Owen et al.
1995; Sweeney et al. 2000; Swainson et al. 2001;
Blackwell et al. 2004). However, performance on PAL
has also been shown to engage additional brain
regions comprising the frontoparietal network during
encoding phases, and posterior cingulate and left
cuneus regions during retrieval stages (de Rover et al.
2011). Outcome measures assessed were errors made
at the six-pattern and eight-pattern stage (adjusted),
total errors (adjusted), mean trials to success, and
ﬁrst trial memory score.
Stroop test
The Stroop is a test of executive function and assesses
selective attention and response inhibition. Inhibition
of the prepotent response in the interference stage of
the Stroop primarily engages the anterior cingulate
cortex (ACC), with general Stroop performance also
requiring input from regions of the temporal and par-
ietal lobes (Botvinick et al. 2004; Alvarez & Emory,
2006; Strauss et al. 2006). The computerized Stroop
test used in the current study is based on the Victoria
Stroop Test (VST) as described previously (Assef
et al. 2007). Response speed in milliseconds is recorded
on each trial with an overall mean response time
(MRT) for each of three stages [Stage 1, word naming;
Stage 2, colour naming; Stage 3 (interference stage),
naming the colour of an incongruent word, for
example the word ‘blue’ printed in the colour red],
consisting of 24 trials. The main outcome measure is
the ‘Stroop effect’, calculated by subtracting the MRT
of Stage 1 from the MRT on Stage 3 (Assef et al. 2007).
IED
IED is a test of executive function and assesses rule
acquisition and reversal, attentional set formation,
maintenance and shifting (Downes et al. 1989;
Sahakian & Owen, 1992). Reversal learning has been
shown to involve the ventral prefrontal cortex (PFC)
whereas the dorsolateral PFC is engaged during atten-
tional set-shifting (Nagahama et al. 2001). The outcome
measures assessed were reversal learning (errors
made on stages 2, 5, 7 and 9) and attentional ﬂexibility
(errors made on stages 6 and 8), as described
previously (Mehta et al. 1999; Rahman et al. 1999),
and total errors (adjusted).
SWM
SWM is a test of working memory, involving online
monitoring and updating of information and self-
ordered searching, and has shown sensitivity to frontal
lobe dysfunction (Owen et al. 1996; Robbins et al. 1998).
The outcome measures assessed were total between-
search errors, total errors and strategy score.
Statistical analysis
As the CANTAB variables were not normally distribu-
ted, the following transformations were applied. IED
and PAL outcome variables were normalized using
log10 transformations and SWM outcome variables
were normalized using square-root transformations.
The Stroop was completed by 38 controls, 38 IBS
patients and 18 CD patients, and data were analysed
excluding the three participants who did not complete
the test. The χ2 test was used to examine the gender
distribution across groups. A one-way ANOVA was
used to explore differences in participant waking
times, group characteristics (age, IQ, BMI, units
of alcohol per week), HADS-anxiety (HADS-A),
HADS-depression (HADS-D) and PHQ-9 scores,
and to assess individual measures of the PAL, IED,
SWM and Stroop tests, followed by Tukey’s Honestly
Signiﬁcant Difference (HSD) post-hoc test or Dunnett’s
t contrasts, as appropriate. As this was an exploratory
study, we have not speciﬁed a single study end-point
and did not adjust for multiple end-points in a full fac-
torial model (Bender & Lange, 2001; Feise, 2002)
to allow detection of possible differences in cognitive
performance on each test within our study population.
Total cortisol levels across each collection time point
were determined using an area under the curve with
respect to ground (AUCg) calculation (Pruessner et al.
2003). AUCg cortisol levels were transformed using a
natural log (ln) to correct positive skew and improve
homogeneity of variance, followed by a one-way
ANOVA and Dunnett’s t contrasts to identify patient
versus control differences. Saliva samples were pro-
vided by 32 healthy controls, 36 IBS patients and
17 CD patients as instructed and useable for analy-
sis. Correlation analyses were carried out using
Spearman’s ρ within each group (control/IBS/CD) to
examine the inﬂuence of total morning cortisol levels
(AUCg), IQ, anxiety (HADS-A), depression (HADS-D;
PHQ-9), duration of disease, current abdominal pain
severity in patients with IBS, and HBI total scores in
CD patients on cognitive performance. Finally, as an
additional measure to control for the inﬂuence of levels
of anxiety or depression on cognitive performance,
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participants meeting predeﬁned criteria for possible
co-morbid depression (a PHQ-9 score of 510;
Kroenke et al. 2001) and/or co-morbid anxiety (a
HADS-A score of 511; Snaith, 2003) were excluded,
and a one-way ANOVA along with Tukey compari-
sons and Dunnett’s t contrasts was carried out on
CANTAB and Stroop outcomes, where group differ-
ences had been identiﬁed with all participants
included. Sample size was determined using a power
calculation to detect signiﬁcant group differences at
an α level of 0.05. The study was not powered to detect
subgroup differences among IBS patients, although
this information was recorded. Non-transformed data
are presented as mean±standard error of the mean
(S.E.M.). Effect sizes are reported as partial eta squared
(ηp
2). All statistical procedures were carried out using
SPSS version 20.0 (SPSS Inc., USA).
Results
Sample characteristics
Group characteristics for healthy control participants,
IBS patients and CD patients are presented in
Table 1. Groups did not differ signiﬁcantly on age,
IQ, BMI or number of units of alcohol consumed per
week. One patient with CD was using budesonide
(Entocort EC) at the time of testing. According to
Rome III criteria, seven IBS patients were diarrhoea
predominant (IBS-D), four constipation predominant
(IBS-C) and 28 were mixed (IBS-M). Patients with
IBS (p<0.001) and patients with CD (p=0.02) scored
higher on the HADS-D than the healthy controls.
Patients with IBS scored signiﬁcantly higher on the
PHQ-9 depression scale (p<0.001) and the HADS-A
(p<0.001) than the healthy controls.
Cognitive performance
Visuospatial episodic memory (PAL)
Comparisons of the number of errors committed at
each individual stage showed that the six-pattern
stage (F2,94=3.43, p=0.03, ηp
2 =0.07; Fig. 1 a), but not
the eight-pattern stage (F2,94=0.02, p=0.98; Fig. 1 b),
differentiated patients from healthy controls. Post-hoc
exploration of this group effect at the six-pattern
stage using Tukey comparisons found that patients
with IBS exhibited signiﬁcantly (p=0.03) impaired
visuospatial memory performance compared to con-
trols but not to patients with CD (p=0.97). Patients
with CD did not differ from controls in the number
of errors made at the six-pattern stage (p=0.2).
There was no overall effect of group on total errors
(F2,94=0.46, p=0.63, ηp
2 =0.01; Fig. 1 c), mean number
of trails to success (F2,94 =1.05, p=0.35, ηp
2 =0.02;
Fig. 1d) or ﬁrst trial memory score (F2,94=1.17,
p=0.32, ηp
2 =0.02; Fig. 1 e).
Selective attention and response inhibition (Stroop)
Group differences on the Stroop effect approached sig-
niﬁcance (F2,91=3.04, p=0.052, ηp
2 =0.06). Inspection of
post-hoc Tukey comparisons showed that patients
with CD (p=0.04), but not patients with IBS (p=0.9),
Table 1. Comparison of group demographics and clinical characteristics
Healthy controls
(n=40) IBS (n=39) CD (n=18) p value
Age (years) 28.3±1.43 28.21±1.19 32.67±2.11 0.14
Gender
Male 11 (27.5) 6 (15.4) 11 (61.1)
Female 29 (72.5) 33 (84.6) 7 (38.9) 0.002
BMI (kg/m2) 23.55±0.59 23.74±0.63 25.23±0.73 0.23
WAIS-R full-scale IQ (NART conversion) 108.57±1.07 105.48±1.39 103.39±2.54 0.07
HADS-D 0.85±0.15 3.85±0.46 2.99±0.70 <0.001
HADS-A 4.30±0.4 8.21±0.74 6.67±3.45 <0.001
PHQ-9 2.03±0.36 6.1±0.86 3.89±0.94 <0.001
Disease duration (years) – 9.13±1.13 9.72±1.63
Current pain, abdominal pain severity (0–100) – 34.75±4.65 –
HBI total score (remission<5) – – 1.89±0.31
IBS, Irritable bowel syndrome; CD, Crohn’s disease; BMI, body mass index; WAIS-R, Wechsler Adult Intelligence Scale –
Revised; NART, National Adult Reading Test; HADS-A/D, Hospital Anxiety and Depression Scale –Anxiety/ Depression;
PHQ-9, nine-item Patient Health Questionnaire; HBI, Harvey Bradshaw Index.
Data are given as n (%) or mean±standard error of the mean (S.E.M.).
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were signiﬁcantly less able to cope with Stroop inter-
ference than healthy controls (Table 2).
Executive function (IED)
Groups did not differ signiﬁcantly on total stages com-
plete (F2,94 =0.04, p=0.9, ηp
2 =0.001), measures of rever-
sal learning (F2,94 =0.68, p=0.51, ηp
2 =0.01), attentional
ﬂexibility (F2,94 =0.053, p=0.95, ηp
2 =0.001) or the total
number of errors across all stages of the IED test
(F2,94=0.16, p=0.85, ηp
2 =0.003; see Table 2 for mean
scores).
SWM
No signiﬁcant main effect of group was found for the
SWM strategy test (F2,94 =0.92, p=0.4, ηp
2 =0.02), total
between errors (F2,94=1.45; p=0.24, ηp
2 =0.03) or total
errors across each stage (F2,94=1. 36; p=0.26, ηp
2 =0.02,
see Table 2 for mean scores).
(a) (b) (c)
(d) (e)
Fig. 1. Group comparison of visuospatial episodic memory performance on the Paired Associates Learning (PAL) test.
(a) Mean errors at the six-pattern stage [* p<0.05, irritable bowel syndrome (IBS) versus control]; (b) mean errors at the
eight-pattern stage; (c) mean total errors; (d) average trials needed to successfully complete each stage; (e) average number of
correct choices on the ﬁrst trial of each stage; lower score=poorer performance. CD, Crohn’s disease. Data are presented as
mean±standard error of the mean (S.E.M.).
Table 2. Summary of mean test scores on the Stroop, IED and SWM
Cognitive test Control IBS CD
Stroop effect (ms) 297.55±29.22 320.31±38.96 463.89±81.52*
IED
Stages complete 8.5±0.14 8.5±0.14 8.44±0.2
Total errors (adjusted) 24.67±3.23 24.51±3.25 27.17±4.67
Reversal learning (errors) 5.05±0.44 6.23±0.92 7.67±2.17
Attentional ﬂexibility (errors) 11.92±1.72 10.79±1.54 11.89±2.43
SWM
Total between errors 18.57±2.81 23.43±2.57 25.44±4.62
Total errors 19.4±3.02 24.15±2.68 26.5±4.81
Strategy score 30.25±1.04 31.9±0.99 29.78±1.63
IED, Intra-Extra Dimensional Set Shift; SWM, Spatial Working Memory; IBS, irritable bowel syndrome; CD, Crohn’s
disease.
* p<0.05 v. control.
Data are given as mean±standard error of the mean (S.E.M.).
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Morning cortisol levels
Waking times for healthy controls (mean=0813
h±13min), patients with IBS (mean=0820 h±14min)
and patients with CD (mean=0808 h±26min) were
not signiﬁcantly different (F2,82=0.12, p=0.89). Total
morning cortisol levels (AUCg) differed signiﬁcantly
between patients and controls (F2,82 =13.71, p<0.001,
ηp
2 =0.25; Fig. 2). Post-hoc analysis using Dunnett’s t con-
trasts against controls showed that patients with IBS
(p=0.03) and patients with CD (p<0.001) exhibited
lower total cortisol levels across the three measurement
time points in comparison to healthy controls.
Correlation analysis
A correlation analysis was carried out to identify
relationships between visuospatial memory perform-
ance (errors at the PAL six-pattern stage), selective
attention and response inhibition (the Stroop test),
total morning cortisol levels (AUCg), IQ (WAIS-R),
levels of anxiety (HADS-A) and levels of depression
(HADS-D, PHQ-9). A signiﬁcant negative relationship
was identiﬁed between AUCg and visuospatial mem-
ory performance within the IBS group but not in the
healthy control participants or the patients with CD
(Table 3). Additional correlations were carried out
within the patient groups to examine the relationship
between disease duration, current abdominal pain
(IBS patients) and HBI (CD patients), and cognitive
performance. Within the IBS group, no signiﬁcant
relationships were identiﬁed between disease duration
or current abdominal pain and PAL six-pattern errors
(both p>0.05). Similarly, within the CD group, no sig-
niﬁcant relationship was identiﬁed between disease
duration or HBI scores and Stroop performance (both
p>0.05).
Cognitive performance after controlling for
psychiatric co-morbidity
To further control for any inﬂuence of levels of
depression and anxiety on cognitive performance, par-
ticipants meeting the predeﬁned criteria for psychiatric
co-morbidity (PHQ-9 score of510; Kroenke et al. 2001)
and/or co-morbid anxiety (HADS-A score of 511;
Snaith, 2003) were excluded and we reanalysed the
number of errors made at the PAL six-pattern stage
and the performance on the Stroop interference test.
The predeﬁned criteria for psychiatric co-morbidity
were met by 16 (41.02%) of the IBS patients and
ﬁve (27.78%) of the CD patients but none of the control
participants. Reanalysis using ANOVA showed that
group differences on visuospatial episodic memory
performance (errors at PAL six-pattern stage; control:
n=40, IBS: n=23, CD: n=13) remained signiﬁcant
(F2,73=3.39, p=0.03, ηp
2 =0.08). Post-hoc analysis using
Tukey comparisons showed that patients with IBS
and without psychiatric co-morbidity made signiﬁ-
cantly more errors at the PAL six-pattern stage than
healthy controls (p=0.04). Overall, group differences
on selective attention and response inhibition
(Stroop interference effect; control: n=38, IBS: n=22,
CD: n=13), after controlling for psychiatric co-
morbidity, did not reach signiﬁcance (F2,70=2.11; p=
0.129, ηp
2 =0.57). However, post-hoc inspection of
Dunnett’s t contrasts showed that patients with CD
without psychiatric co- morbidity, when compared to
healthy control participants, still exhibited reduced
attentional capacity, as they continued to be signiﬁ-
cantly less able to manage Stroop interference than
controls (p=0.04).
Discussion
In this study we tested the hypothesis that IBS is
associated with cognitive impairment. We used
CANTAB, a highly standardized and well-validated
cognitive test battery (Strauss et al. 2006), to assess per-
formance in IBS and CD in comparison with healthy
controls across several cognitive domains including
reversal learning and attentional ﬂexibility (IED),
selective attention and response inhibition (Stroop),
working memory (SWM) and visuospatial episodic
memory (PAL). To our knowledge, this is the ﬁrst
time that such a detailed cognitive assessment has
been performed in either condition.
In support of our main hypothesis, we have shown
that patients with IBS exhibit a subtle deﬁcit in visuo-
spatial episodic memory functioning, which was clear
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Fig. 2. Group comparison of total morning cortisol levels
determined using an area under the curve with respect to
ground (AUCg) calculation on all three measurement points
in healthy control participants (n=34), patients with irritable
bowel syndrome (IBS; n=36) and patients with Crohn’s
disease (CD; n=17). * p<0.05, *** p<0.001 versus control.
Data are presented as mean±standard error of the mean
(S.E.M.).
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at the six-pattern stage of PAL. Performance on PAL
is highly dependent on the functioning of the hippo-
campus (de Rover et al. 2011), a brain region that is
intrinsically involved in the negative feedback regu-
lation of the HPA axis and where glucocorticoid recep-
tors are highly expressed (McEwen, 1999). In our
sample, patients with IBS exhibited lower basal morn-
ing cortisol levels in comparison to healthy controls, a
ﬁnding that is in support of some (Bohmelt et al. 2005;
Suarez-Hitz et al. 2012), but not all (Chang et al. 2009),
previous reports. Nonetheless, these results add to the
well-acknowledged view that HPA-axis dysfunction is
a key feature of IBS (Mayer et al. 2001). Furthermore,
our ﬁnding of a relationship between morning cortisol
levels and performance on the PAL test is in line with
many preclinical (Song et al. 2006; Sterlemann et al.
2010) and human studies (Lupien et al. 2009) that
have documented the negative impact of HPA-axis
dysregulation on hippocampal-mediated cognitive
performance. Our results suggest that lower cortisol
levels are associated with increased PAL errors in IBS,
and this is in line with the commonly acknowledged
inverted U-shape function of cortisol on hippo-
campal-mediated memory performance, where both
abnormally elevated and blunted cortisol levels are
associated with cognitive dysfunction (de Kloet et al.
1999; Wolf, 2003; Lupien et al. 2007). Indeed, previous
cognitive assessments in IBS (Gomborone et al. 1993;
Gibbs-Gallagher et al. 2001; Afzal et al. 2006; Posserud
et al. 2009; Martin & Chapman, 2010; Chapman &
Martin, 2011), together with our ﬁndings, suggest
that IBS may be associated with both emotionally
modulated cognitive alterations mediated by amygda-
lar regions and non-emotional visuospatial episodic
memory alterations mediated by the hippocampus.
Brain imaging studies have suggested a key role for
the ACC in abnormal central processing of visceral
pain in IBS (Mayer et al. 2009). Patients with IBS in
our sample did not exhibit deﬁcits on the Stroop test,
which heavily engages the ACC during the interfer-
ence stages (Alvarez & Emory, 2006), suggesting that
the ACC is unaffected at the cognitive level and that
abnormal functioning of this region in IBS is speciﬁc
to altered visceral pain processing. However, sub-
regions of the ACC (the perigenual ACC and anterior
midcingulate cortex) may be functioning differentially
in IBS (Tillisch et al. 2011) and our ﬁndings may simply
reﬂect that the Stroop does not fully engage these par-
ticular regions. Furthermore, it should be noted that
altered visceral pain processing may be apparent in
only a subset of patients with IBS (Quigley, 2006)
and, as such, it is possible that only a subset of
patients, not represented in our sample, may exhibit
ACC-related cognitive deﬁcits.
Altered cognitive ﬂexibility on the WCST, accom-
panied by reduced right dorsolateral PFC activity,
has recently been described in IBS (Aizawa et al.
2012). By contrast, we found no deﬁcit in reversal learn-
ing or cognitive ﬂexibility on the IED, which is con-
sidered to be an analogue of the WCST (Robbins
et al. 1998). Furthermore, the SWM and IED tasks
engage the mid-dorsolateral/ventral PFC and the
dorsolateral PFC respectively (Owen et al. 1995;
Nagahama et al. 2001). As no group differences were
identiﬁed on either of these tests, we found no evi-
dence to support a general decrement in dorsolateral
PFC-mediated cognitive function. Explanations for
these disparate results may include the heterogeneity
of IBS, differences in central functioning between IBS
subtypes, temporal symptom ﬂuctuations or subtle
Table 3. Summary of correlations between cognitive performance (errors at the PAL six-pattern stage and the Stroop test) and morning cortisol
levels, IQ and clinical characteristics
Measure
Errors PAL six-pattern stage Stroop test
Control IBS CD Control IBS CD
Morning cortisol (AUCg) 0.023 −0.367* −0.437 −0.005 −0.013 0.032
WAIS-R IQ −0.237 −0.121 −0.035 0.080 −0.113 0.266
HADS-A (Anxiety) 0.114 0.008 −0.047 0.130 −0.142 0.317
HADS-D (Depression) 0.005 0.066 0.361 0.237 −0.107 0.351
PHQ-9 (Depression) −0.013 0.025 −0.038 0.089 0.072 0.284
Disease duration – 0.18 0.16 – −0.01 0.37
Current abdominal pain – −0.27 – – −0.02 –
HBI – – −0.07 – – −0.20
PAL, Paired Associate Learning; WAIS-R, Wechsler Adult Intelligence Scale –Revised; HADS-A/D, Hospital Anxiety and
Depression Scale –Anxiety/Depression; PHQ-9, nine-item Patient Health Questionnaire; HBI, Harvey Bradshaw Index.
* p<0.05.
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differences in the cognitive requirements for adequate
performance on the IED and the WCST. Therefore,
future studies exploring other aspects of executive
function coupled with functional brain imaging are
needed to clarify the impact, if any, on executive pro-
cesses and other cognitive functions mediated by fron-
tal brain regions in IBS.
In accordance with previous reports, levels of both
depression and anxiety were higher in IBS
(Hazlett-Stevens et al. 2003; Creed et al. 2005, 2008;
Lembo et al. 2009; Mykletun et al. 2010) and depression
was slightly elevated in CD (Goodhand et al. 2012).
Cognitive deﬁcits are well documented in depressive
and anxiety disorders (Austin et al. 2001) and a
relationship between the CAR and hippocampal-
mediated cognition in unmedicated depressed patients
has been described recently (Hinkelmann et al. 2013). It
is important to note that the cognitive deﬁcits most
clearly exhibited by patients with IBS (visuospatial epi-
sodic memory; PAL) and by patients with CD (Stroop
interference) persisted after removal of patients ex-
hibiting possible psychiatric co-morbidity, which
strongly suggests that these deﬁcits are independent
of psychiatric co-morbidity. This result further sug-
gests that a shared underlying pathophysiological
mechanism, such has heightened levels of pro-
inﬂammatory cytokines, which have been identiﬁed
in both IBS (Dinan et al. 2006; Liebregts et al. 2007;
Dinan et al. 2008; Scully et al. 2010; McKernan et al.
2011) and depression (Raison et al. 2006) and can
impact on cognitive performance (Kennedy et al.
2012), may play a pivotal role in mediating the simi-
larities in cognitive deﬁcits identiﬁed in each disorder.
Moreover, it is likely that similarities in cognitive dys-
function described here in IBS not only apply to
depression but also overlap with other functional or
psychiatric disorders in which stress, immune acti-
vation or altered central pain processing is implicated
in the underlying pathophysiology. However, a note
of caution is warranted in this interpretation as there
is continuing debate in the literature as to the latent
structure of the HADS and its utility in differentiating
and detecting clinically relevant levels of anxiety and
depression (Coyne & van Sonderen, 2012a,b; Norton
et al. 2012). Hence, future studies with a speciﬁc
focus on identifying the shared and differential cogni-
tive deﬁcits associated with IBS and related psychiatric
conditions are needed, with psychiatric status being
formally determined using a SCID.
Of note, patients with CD exhibited a reduction in
their capacity to cope with Stroop interference when
compared to healthy control participants. They did
not, however, exhibit visuospatial memory impair-
ment. This suggests a disorder-speciﬁc mechanism
by which HPA-axis dysfunction can impact neuro-
biologically on cognitive performance. Cognitive func-
tion in IBD has not been well characterized, with only
one study in the literature, lacking a healthy control
comparison group, reporting a beneﬁcial outcome of
iron replacement therapy on cognitive performance
in anaemic patients with CD (Wells et al. 2006).
However, brain morphological abnormalities have
recently been reported in CD (Agostini et al. 2013)
and a subsequent review article has proposed that
CD may be associated with altered cognitive perform-
ance due to these abnormalities (Vogt, 2013). Our
results lend substantial support to this hypothesis
and indicate that further investigations are needed at
a structural and functional brain-imaging level to
deﬁnitively link poor cognitive performance to the pro-
posed morphological brain changes in CD.
A limitation of our study is the heterogeneous nature
of our IBS population. There is some evidence to
suggest that psychiatric diagnoses and possibly central
functioning varies between IBS-D, IBS-C and IBS-A
subtypes (Tillisch et al. 2005). Future studies, ade-
quately powered to detect subgroup differences of cog-
nitive performance in IBS, are needed, in addition to
detecting potential differences in PAL performance
between patients with CD and controls and patients
with CD and IBS. In addition, the inclusion of patients
with active and inactive CD and ulcerative colitis, in
conjunction with a more temporally speciﬁc measure
of GI symptoms than the HBI, will be important in
identifying whether cognitive differences exist between
the two categories of IBD, due to disease activity and
general GI symptomatology. Our results suggest that
CD patients exhibit some differences in cognitive per-
formance on the PAL and future studies should aim
to explore this possibility in more detail. Whether the
cognitive alterations identiﬁed here are state or trait
cognitive markers requires further investigation by
prospective and longitudinal study designs, particu-
larly in relation to the potential impact of ﬂuctuating
symptoms and their severity on cognitive performance
in IBS.
Our groups differed with regard to gender and it is
important to note that gender differences in brain
responses to visceral pain stimulation have been
observed in IBS (Berman et al. 2000; Naliboff et al.
2003). Although small, and notably inconsistent, gen-
der differences on visual–spatial tasks such as tests of
spatial orientation or verbal abilities in healthy popu-
lations are commonly reported in the literature
(Weiss et al. 2003), the inﬂuence of gender on visuo-
spatial episodic memory performance in the PAL, to
the best of our knowledge, has not been speciﬁcally
investigated. It is therefore difﬁcult to know whether
gender differences impacted on our results, and future
studies should aim to delineate the effects of gender on
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performance on the PAL and other assessments in
IBS. Such studies will also need to examine the role
that important factors such as age and menstrual
cycle may play in cognitive performance in IBS.
In conclusion, IBS patients in the current study
displayed a subtle but signiﬁcant deﬁcit on a
hippocampal-mediated test of visuospatial episodic
memory, which was related to morning cortisol
levels and independent of psychiatric co-morbidity.
Our results must be considered preliminary and this
study as exploratory, and there is a clear need for
follow-up studies to conﬁrm these ﬁndings and to
address the limitations discussed. Nonetheless, when
considering that IBS is a common disorder and
typically emerges in young adults who are involved
in formal education or are in an early phase of career
development, assessing the impact of IBS on cognition
is of paramount importance. Daily stressors play a key
role in exacerbating symptoms in IBS (Levy et al. 1997;
Bennett et al. 1998) and our results suggest that, from a
clinical point of view, therapies aimed at reducing
stress or normalizing HPA-axis functioning should be
considered a key line of treatment to reduce not only
the impact on GI symptoms in IBS but also the central
impact on cognitive function. Our results also have
important implications for individuals who suffer
from CD, which need to be addressed. Finally, in keep-
ing with our primary hypothesis, these data support
the view that IBS is a disorder associated with cogni-
tive impairment (Kennedy et al. 2012) and warrant
further investigation to identify the neurobiological
mechanisms inﬂuencing cognitive performance in
this debilitating disorder of the brain–gut axis.
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